Phio Pharmaceuticals Net Worth

Phio Pharmaceuticals Net Worth Breakdown

The net worth of Phio Pharmaceuticals Corp is the difference between its total assets and liabilities. Phio Pharmaceuticals' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Phio Pharmaceuticals' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Phio Pharmaceuticals' net worth can be used as a measure of its financial health and stability which can help investors to decide if Phio Pharmaceuticals is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Phio Pharmaceuticals Corp stock.

Phio Pharmaceuticals Net Worth Analysis

Phio Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Phio Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Phio Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Phio Pharmaceuticals' net worth analysis. One common approach is to calculate Phio Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Phio Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Phio Pharmaceuticals' net worth. This approach calculates the present value of Phio Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Phio Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Phio Pharmaceuticals' net worth. This involves comparing Phio Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Phio Pharmaceuticals' net worth relative to its peers.

Enterprise Value

(7.22 Million)

To determine if Phio Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Phio Pharmaceuticals' net worth research are outlined below:
Phio Pharmaceuticals had very high historical volatility over the last 90 days
Phio Pharmaceuticals has some characteristics of a very speculative penny stock
Net Loss for the year was (10.83 M) with loss before overhead, payroll, taxes, and interest of (7.01 M).
Phio Pharmaceuticals Corp currently holds about 18.02 M in cash with (10.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Phio Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Latest headline from Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
Phio Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Phio Pharmaceuticals Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Phio Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of March 2024
Upcoming Quarterly Report
9th of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
27th of March 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Know Phio Pharmaceuticals' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Phio Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Phio Pharmaceuticals Corp backward and forwards among themselves. Phio Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Phio Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Blackrock Inc2024-03-31
Sabby Management Llc2024-03-31
Citigroup Inc2023-12-31
Renaissance Technologies Corp2024-03-31
Morgan Stanley - Brokerage Accounts2024-03-31
Anson Funds Management Lp2024-03-31
Geode Capital Management, Llc2023-12-31
Jpmorgan Chase & Co2023-12-31
Virtu Financial Llc2024-03-31
30.9 K
Cetera Advisors Llc2024-03-31
30.4 K
Cetera Investment Advisers2024-03-31
30.4 K
Note, although Phio Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Phio Pharmaceuticals' market capitalization trends

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.27 M.

Market Cap

1.5 Million

Project Phio Pharmaceuticals' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(1.16)(1.21)
Return On Capital Employed(1.38)(1.31)
Return On Assets(1.16)(1.21)
Return On Equity(1.40)(1.33)
When accessing Phio Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Phio Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Phio Pharmaceuticals' profitability and make more informed investment decisions.
The data published in Phio Pharmaceuticals' official financial statements typically reflect Phio Pharmaceuticals' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Phio Pharmaceuticals' quantitative information. For example, before you start analyzing numbers published by Phio accountants, it's essential to understand Phio Pharmaceuticals' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.

Evaluate Phio Pharmaceuticals' management efficiency

Phio Pharmaceuticals Corp has return on total asset (ROA) of (0.6965) % which means that it has lost $0.6965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4523) %, meaning that it created substantial loss on money invested by shareholders. Phio Pharmaceuticals' management efficiency ratios could be used to measure how well Phio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of June 2024, Return On Tangible Assets is likely to drop to -1.21. In addition to that, Return On Capital Employed is likely to grow to -1.31. At this time, Phio Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 22nd of June 2024, Total Current Assets is likely to grow to about 12.1 M, while Non Current Assets Total are likely to drop about 39.9 K.
Last ReportedProjected for Next Year
Book Value Per Share 3.71  3.52 
Tangible Book Value Per Share 3.71  3.52 
Enterprise Value Over EBITDA 0.65  0.69 
Price Book Value Ratio 0.20  0.19 
Enterprise Value Multiple 0.65  0.69 
Price Fair Value 0.20  0.19 
Enterprise Value-6.9 M-7.2 M
The analysis of Phio Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Phio Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Phio Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue
Return On Equity
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Phio Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Phio Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Phio Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Robert Bitterman over two weeks ago
Acquisition by Robert Bitterman of 1000 shares of Phio Pharmaceuticals at 0.74 subject to Rule 16b-3
Robert Bitterman over two weeks ago
Acquisition by Robert Bitterman of 1000 shares of Phio Pharmaceuticals at 0.75 subject to Rule 16b-3
Robert Bitterman over a month ago
Acquisition by Robert Bitterman of 40000 shares of Phio Pharmaceuticals subject to Rule 16b-3
Robert Bitterman over two months ago
Acquisition by Robert Bitterman of 2000 shares of Phio Pharmaceuticals at 0. subject to Rule 16b-3
Robert Bitterman over two months ago
Acquisition by Robert Bitterman of 300000 shares of Phio Pharmaceuticals at 0.1 subject to Rule 16b-3
Robert Bitterman over three months ago
Acquisition by Robert Bitterman of 2500 shares of Phio Pharmaceuticals at 0.91 subject to Rule 16b-3
Robert Bitterman over three months ago
Disposition of 1804 shares by Robert Bitterman of Phio Pharmaceuticals at 0.76 subject to Rule 16b-3
Caitlin Kontulis over three months ago
Disposition of 523 shares by Caitlin Kontulis of Phio Pharmaceuticals at 0.66 subject to Rule 16b-3
Caitlin Kontulis over three months ago
Disposition of 658 shares by Caitlin Kontulis of Phio Pharmaceuticals at 0.65 subject to Rule 16b-3
Caitlin Kontulis over six months ago
Payment of 335 shares by Caitlin Kontulis of Phio Pharmaceuticals subject to Rule 16b-3
Ferrara Robert L over a year ago
Purchase by Ferrara Robert L of 2000 shares of Phio Pharmaceuticals
Caitlin Kontulis over a year ago
Payment of 335 shares by Caitlin Kontulis of Phio Pharmaceuticals subject to Rule 16b-3
Phio Pharmaceuticals time-series forecasting models is one of many Phio Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Phio Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Phio Pharmaceuticals Earnings per Share Projection vs Actual

Phio Pharmaceuticals Corporate Management

Jim CardiaVP OperationsProfile
Caitlin KontulisVP SecretaryProfile
Dr MedScInterim DirectorProfile
Linda MahoneySenior DevelopmentProfile

Additional Information and Resources on Investing in Phio Stock

When determining whether Phio Pharmaceuticals Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phio Pharmaceuticals Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phio Pharmaceuticals Corp Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.